ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in an encapsulation device. Data in their publications demonstrate that these cells can produce therapeutically relevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications.

China Tobacco Yunnan Industrial Co. Ltd. is a company headquartered in China ultimately controlled by the Government of China. The firm manufactures tobacco products.

BioLamina AB develops, manufactures and markets cell culture reagents intended for culturing of primary cells. Its applications animal stem cells, cancer cells, cardiac applications, clonal applications, endothelial applications, epithelial applications, expansion of human PSC, eye applications, hepatic applications, intestinal applications, kidney cell culture, lung applications, neural applications, pancreatic applications and skeletal muscle applications. The company was founded by Kristian Tryggvason and Karl Tryggvason in 2008 and is headquartered in Sundbyberg, Sweden.

Cellectis AB, a subsidiary of Takara Holdings, Inc., is a Swedish company located in Gothenburg. The firm manufactures and distributes stem cell-related products. On September 04, 2014 Takara Bio, Inc. acquired Cellectis AB from Cellectis SA.

Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines.

Shenzhen Jiatianyuan Biotechnology Co., Ltd., established on 2005-04-19, Business scope includes general business items:Research on biological gene technology and products,development and sales(Does not contain franchise,Exclusive control,Monopoly);engaged in goods,Technology import and export business(law,Administrative regulations,Except for items prohibited by the State Council,Restricted projects must obtain a license before operating).,The licensing program is:

Protein Sciences was founded in 1983 and has over 30 years of experience in developing vaccines and biopharmaceuticals for the prevention and treatment of a variety of diseases. They use their proprietary BEVS protein expression technology to produce high quality recombinant proteins quickly, reliably and at low cost.

Cellular Dynamics International Inc., (CDI) is a developer and manufacturer of fully functioning cells in industrial quantities to precise specifications. CDI's proprietary products include true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell Products). CDI's products provide standardized, easy-to-use, cost-effective access to the human cell, the smallest fully functioning operating unit of human biology. Customers use our products, among other purposes, for drug discovery and screening, to test the safety and efficacy of their small molecule and biological drug candidates, for stem cell banking, and in the research and development of cellular therapeutics.

Shanghai Personal Biotechnology Co. Ltd. manufactures nutritional beauty products. Its products include high throughput sequencing, conventional molecular biology services, and conventional sequencing and synthesis. The company was founded in April 2011 and is headquartered in Shanghai, China.

Lance Cell Biotechnology (Guangzhou) Co., Ltd., established on 2017-09-14, The business scope includes the development and application of human stem cell technology;R&D and application of cell technology;Development of Human Gene Diagnosis and Therapy Technology;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Biomass Energy Technology Services;Biochemical product technology research and development;New material technology research and development;3Dprint service;Food Internet Sales(Only sell prepackaged food);food business(Only sell prepackaged food);Sales of Class I Medical Devices;Sales of Class II Medical Devices;Sales of hygiene products and single-use medical products;Health Care Services(non-medical);Traditional Chinese Medicine Health Care Services(non-medical);Nursing facility services(Does not include medical services);Remote Health Management Services;Health Consulting Services(Does not include medical services);Sports Health Service;Medical Research and Experimental Development;Engage in investment activities with own funds;Domestic trade agent;trade broker;Information Technology Consulting Services;Cosmetics Wholesale;Cosmetics Retail;Sales of electrical machinery and equipment;Sales of electronic special equipment;electronics sales;Instrument sales;Optical Instrument Sales;internet sales(Except for products that require a license for sale);Personal Internet Live Streaming Service(Need to record);Sales of electronic measuring instruments;Sales of electrical instruments and meters;Wholesale of electronic components;Production of hygiene products and single-use medical products;Health food sales;Class III medical device business;Internet Information Service for Medical Devices;Import and export;liquor business;Inspection and testing service;Internet hospital services relying on physical hospitals

Union Stem Cell & Gene Engineering Co., Ltd. engages in the development of stem cell therapeutic products. Its business activities include stem cell resource conservation, stem cell clinical transplant, and research and development of monoclonal antibodies treatment and gene chip. The company was founded on February 16, 2001 and is headquartered in Tianjin, China.

Shanghai Nier Biotechnology Co., Ltd., established on 2021-02-25, Business scope includes licensed projects:Import and export;Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments) General project:Engaged in technology development in the field of biotechnology,technical consulting,Technical Services,technology transfer;Business Consulting;Class I medical device,Chemical raw materials and products(Removal of hazardous chemicals,Monitor Chemicals,firecrackers,civilian explosives,precursor chemicals),Instrumentation,Electrical Equipment,laboratory equipment,Daily necessities,Wholesale and retail of Wujinjiaodian.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Miltenyi Biotec, Inc. provides equipment and related services for biomedical research. The company was founded on April 2, 1992 and is headquartered in Auburn, CA.

Beijing Keyu United Stem Cell Biotechnology Co., Ltd., established on 2006-04-21, Business scope includes technology development,technology transfer,Technical Services,Information Consulting;Import and export,Technology Import and Export,Agent import and export.(non-patent technology investment125ten thousand yuan;the enterprise2006year04moon21Currently a domestic enterprise,At2006year04moon21Changed to a foreign-invested enterprise.)

Shenyang Amyao Bioengineering Technology R&D Center Co., Ltd., established on 2017-03-14, Business scope includes bioengineering technology,computer software technology,cell therapy technology,Growth factor technology research and development;Biological product,medical instruments,cosmetic,Healthy food,Research and development of laboratory equipment,Production,Sales and technical consultation,Technical Services,technology transfer;Self-operated and agent import and export business of various commodities and technologies;electronic product,Electrical Equipment,printing device,Communication equipment,stationery,Biological reagents and consumables,Chemical raw materials(Free of Hazardous Chemicals)Sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.)

Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology. Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers. Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):

Liwo Biotechnology (Shenzhen) Co., Ltd., established on 2016-12-02, Business scope includes general business items:Technology development in the field of biomedicine,technology transfer,technical consulting,Technical Services;R&D and sales of biological reagents and laboratory consumables;sales of cosmetics.,The licensing program is:

In 2009, starting with gene chip technology, Ouyi started its career with the simple idea of providing customers with biotechnology services with quality and temperature. Over the past nine years, we have never changed our original mind. From library technology to gene chip technology, second generation sequencing technology, third generation sequencing technology, and mass spectrometry technology, we have been pioneering in the field of multi-component technology. Through technology development, process optimization, introduction of sophisticated equipment, talent gathering, and continuous management improvement, Ouyi has established high quality standards and strict quality control system, and always adheres to the consistent pursuit of "hard data, good service" to provide customers with quality technical services. Ouyi has successively obtained the qualification of certification service provider in China from American Agilent, American Affymetrix and American Pacbio. It has successively established close industry university research cooperation with Ocean University of China, Institute of Genetics of Chinese Academy of Sciences, etc., and jointly built a joint research and development laboratory with Hitachi Diagnostics. It has successively obtained honorary qualifications such as "Shanghai High tech Enterprise", "Pudong Research and Development Institute", "Specialized and Special New Enterprise", etc. In 2017, Shanghai Luming Biological Holding Co., Ltd. achieved complete omic technical services from genome, transcriptome, epigenome to proteome and metabolome, and established Jingzhuan Pharmaceutical, which achieved a leap from scientific and technological services to precision medicine. On the basis of years of technology accumulation, Ouyi has made every effort to promote the research and development of molecular diagnostic products. Since its establishment, Ouyi has served nearly 10000 customers, more than 1000 user units, and assisted customers in publishing more than 500 SCI papers, Actively participated in and promoted the development of science and technology service industry.

Suzhou Huizhen Biotechnology Co., Ltd., established on 2017-09-04, Business scope includes technology development in the field of biomedical technology,technology transfer,technical consulting,Technical Services;Biological reagents and consumables,medical instruments,Research and Development of Electronic Instruments,Production,Sales;software development,Sales and related technical services;Engaged in the import and export business of the above commodities and technologies;Own house rental.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) licensed items:Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Engineering and Technology Research and Experimental Development;Domestic trade agent;Technology promotion and application services;Technical extension services;Information Technology Consulting Services;R&D of industrial enzyme preparations;Medical Research and Experimental Development;R&D and application of cell technology;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)